Stock Analiz

Immatics N.V. IMTX

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$6.39Market cap $956M
Open the interactive analysis →

Immatics N.V. (IMTX) is a healthcare company listed in the US with a market value of about $956M. In the twelve months to September 30, 2026 it had revenue of $48M and net income of -$252M, a net margin of -526.6%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -87%.

About Immatics

Immatics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 2 of the last 8 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S20.0
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-26.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-87.3%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$48M————————
Net income-$252M-$231M$16M-$105M$30M-$106M-$259M-$35M-$36M
Free cash flow-$248M-$215M-$181M-$14M$101M-$102M-$108M$77M$23M
EPS (diluted)$-1.87$-1.54$0.11$-0.70$0.20$-0.71$-1.73$-0.24$-0.24
Net margin-526.6%————————
ROIC—-37.2%-4.8%-45.6%9.7%-358.6%-79.8%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Immatics pay a dividend?

Not currently.

Is Immatics a good stock to buy?

We do not give buy or sell advice. Immatics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.